Bexarotene pointless against tumor stage mycosis fungoides

Bexarotene.png

According to results from a long-term, single-center study presented at the annual meeting of the American Academy of Dermatology, oral bexarotene therapy offers absolutely nothing to patients diagnosed with tumor stage mycosis fungoides, a rather common subtype of cutaneous T-cell lymphoma.

Patients given oral bexarotene therapy experienced a median survival time of 3.3 years, compared with a median of 7.7 years survival time for patients who did not receive the drug.

Despite the frequency of the diagnosis of mycosis fungoides, no randomized controlled trials exist to compare existing therapies head to head to determine which confers the greatest benefit on the most number of patients.

Source: Family Practice News

LymphomaInfo Social